4-bromo-9a-butyl-7-methoxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one | 371756-92-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 4-bromo-9a-butyl-7-methoxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one
• 英文别名: 4-bromo-9a-butyl-7-methoxy-2,9-dihydro-1H-fluoren-3-one
• CAS: 371756-92-2
• 化学式: C₁₈H₂₁BrO₂
• 分子量: 349.268
• InChiKey: SPAFSWGQVXGSKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-bromo-9a-butyl-7-methoxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one 在 吡啶盐酸盐 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 5.0h， 生成 9a-butyl-4-cyano-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one
  参考文献：
  名称：

  The discovery of tetrahydrofluorenones as a new class of estrogen receptor β-subtype selective ligands

  摘要：

  Synthesis and derivatization of a series of substituted tetrahydrofluorenone analogs giving potent, ERbeta subtype selective ligands are described. Several analogs possessing ERbeta binding affinities comparable to 17beta-estradiol but with greater than 75-fold selectivity over ERalpha are reported.

  DOI：

  10.1016/j.bmcl.2006.03.098
• 作为产物：
  描述：

  2-butyl-5-methoxy-2-(3-oxo-butyl)-1-indanone 在 四氢吡咯 、 溴 、 碳酸氢钠 、 溶剂黄146 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 生成 4-bromo-9a-butyl-7-methoxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one
  参考文献：
  名称：

  The discovery of tetrahydrofluorenones as a new class of estrogen receptor β-subtype selective ligands

  摘要：

  Synthesis and derivatization of a series of substituted tetrahydrofluorenone analogs giving potent, ERbeta subtype selective ligands are described. Several analogs possessing ERbeta binding affinities comparable to 17beta-estradiol but with greater than 75-fold selectivity over ERalpha are reported.

  DOI：

  10.1016/j.bmcl.2006.03.098

文献信息

• Estrogen receptor modulators
  申请人：——

  公开号：US20030027840A1

  公开（公告）日：2003-02-06

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

  本发明涉及化合物及其衍生物、它们的合成方法以及它们作为雌激素受体调节剂的应用。本发明的化合物是雌激素受体的配体，因此可用于治疗或预防与雌激素功能相关的多种疾病，包括：骨丢失、骨折、骨质疏松症、软骨退化、子宫内膜异位症、子宫纤维瘤病、热潮红、LDL胆固醇水平升高、心血管疾病、认知功能损害、脑部退行性疾病、再狭窄、男性乳房发育、血管平滑肌细胞增殖、肥胖、失禁以及癌症，尤其是乳腺癌、子宫癌和前列腺癌。
• EP1257264A4
  申请人：——

  公开号：EP1257264A4

  公开（公告）日：2005-08-10
• ESTROGEN RECEPTOR MODULATORS
  申请人：Merck & Co., Inc.

  公开号：EP1257264A1

  公开（公告）日：2002-11-20
• US7087599B2
  申请人：——

  公开号：US7087599B2

  公开（公告）日：2006-08-08
• [EN] ESTROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS DE RECEPTEURS D'OESTROGENE
  申请人：MERCK & CO INC

  公开号：WO2001082923A1

  公开（公告）日：2001-11-08

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.